Pfizer
$32.859876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$32.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.12 (+3.53%) Today
-$0.02 (-0.06%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell Pfizer and other stocks, options, ETFs, and crypto commission-free!
About PFE
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. Read More The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Employees
88,300
Headquarters
New York, New York
Founded
1849
Market Cap
176.14B
Price-Earnings Ratio
11.07
Dividend Yield
4.79
Average Volume
42.61M
High Today
$33.00
Low Today
$31.75
Open Price
$31.95
Volume
25.78M
52 Week High
$44.56
52 Week Low
$27.88
Collections
PFE News
Reuters12h
BRIEF-Pfizer Receives European Approval For Oncology Biosimilar, Ruxience
April 2 (Reuters) - Pfizer Inc:
* PFIZER RECEIVES EUROPEAN APPROVAL FOR ONCOLOGY BIOSIMILAR, RUXIENCEâ„¢ (RITUXIMAB)
* PFIZER RECEIVES EUROPEAN APPROVAL FOR ONC
Analyst Ratings
50%
of 14 ratings
Buy
50%
Hold
50%
Sell
0%
PFE Earnings
$0.00
$0.28
$0.57
$0.85
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Available Apr 28, Pre-Market
